← Back to headlines
Kairos Pharma Acquires Exclusive Worldwide Rights to CL-273
Kairos Pharma has signed a binding strategic asset acquisition for exclusive worldwide rights to CL-273 from Orbimed and Torrey Pines Investment-backed Celyn Therapeutics.
2 Mar, 14:11 — 2 Mar, 14:11
Related Stories
US and Iran Exchange Strikes as Markets React to Escalation
13m ago
BP Appoints Ian Tyler as New Chairman Following Leadership Transition
37m ago
Everus Construction and California Resources Finalize Major Corporate Acquisitions
56m ago
Nvidia Nears $14 Billion Acquisition of AI Startup Hugging Face
1h ago